Currently Viewing:
ISPOR 2019
Panelists Discuss the Potential and Pitfalls of Disruption in Healthcare
May 20, 2019
Trends in Value That Dr Daniel Mullins Expects to See in Coming Years
May 21, 2019
Dr Jon Campbell Discusses the Need for More Creative Methods of Value Assessment
May 21, 2019
The Imperfect QALY: How It's Used Depends on Where You Enter Value Discussions
May 21, 2019
Paul Melmeyer: Value Assessments Need to Take Into Account Unique Characteristics of a Disease
May 22, 2019
Panelists Debate the Role of ICER: Useful Overseer of Prices, or Oppressor of Choice?
May 22, 2019
Bringing Financial Theory Into the Value Equation of Future Cutting-Edge Therapies
May 22, 2019
Dr Devin Incerti Outlines Best Practices for Approaching Value Assessment
May 22, 2019
Biosimilar Experts Give Highlights of US Uptake Issues
May 23, 2019
Dr Nicholas Robert Explains the Benefits, Challenges of Using RWE for Measuring Clinical End Points
May 23, 2019
Dr Eleanor Perfetto Outlines Criticisms of the QALY
May 23, 2019
New Therapies Offer Possible Cures but Pose Affordability Challenges
May 23, 2019
Fremanezumab Cost Effective for Both Types of Migraine, Researchers Say
May 27, 2019
Currently Reading
Dr Jon Campbell on Benefits of Using MCDA in Value Assessment
June 03, 2019
Dr Devin Incerti: Use Value Assessments to Maximize the Well-Being of a Population
July 14, 2019
Dr Nicholas Robert Discusses How Real-World Data Can Complement Clinical Trial Data
July 16, 2019
Dr Eleanor Perfetto on Ways to Improve Transparency, Education Around Value Assessment
July 23, 2019
Dr Nicholas Robert on Lag Time Between Drug Approval, Availability of the Drug in EMRs
July 29, 2019
Dr Nicholas Robert: Lag Time Between a Drug Approval, Availability in EMRs Can Impact Patient Care
August 10, 2019
Dr Nicholas Robert Outlines How Patients Can Provide More Information on Newly Approved Drugs
August 22, 2019

Dr Jon Campbell on Benefits of Using MCDA in Value Assessment

Jonathan Campbell, PhD, associate professor, Department of Clinical Pharmacy, Pharmaceutical Outcomes Research, Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of Colorado, discusses the value of multi-criteria decision analysis (MCDA) in value assessment, as well as lessons learned from using MCDA in other industries.


Jonathan Campbell, PhD, associate professor, Department of Clinical Pharmacy, Pharmaceutical Outcomes Research, Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of Colorado, discusses the value of multi-criteria decision analysis (MCDA) in value assessment, as well as lessons learned from using MCDA in other industries.

Transcript

What elements does multi-criteria decision analysis take into account that traditionally aren't accounted for in value assessments?

We’re going to focus on those components that aren’t common in cost-effectiveness and other understandings that would be considered traditional value. Those criterion include caregiver burden, things like severity of disease, especially in the more severe or rare diseases, this might be a great application. Novelty of therapy is a component, as well as insurance value, the quality of evidence, and even things like patient affordability.

What are some lessons learned from multi-criteria decision analysis being used in other industries, such as investment, that can be applied to its use in healthcare?

We have learned from other fields, operations research, that multi-criteria decision analysis is very applicable in fields where there are basic tradeoffs and tradeoffs between things that some of which may be monetized and others that are difficult to monetize or put dollars to. So, a field like environmental forestry or forestry planning, might be a good example of that, where you have to trade off things where the environment might win or there might be a social norm or understanding around a concept, and compare those things to more measures that are common in economics. So, the things that are monetized.

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up